Efficacy and safety of up to two years of tralokinumab treatment in adults of different racial subgroups with moderate-to-severe atopic dermatitis. (2023). SKIN The Journal of Cutaneous Medicine, 7(2), s144. https://doi.org/10.25251/skin.7.supp.144